Takaaki Fujii, Yuko Nakazawa, Mayu Aoki, Keiko Tanabe, Misato Ogino, Sayaka Obayashi, Ken Shirabe
{"title":"Pegfilgrastim对乳腺癌术前化疗引起的心脏毒性的保护作用","authors":"Takaaki Fujii, Yuko Nakazawa, Mayu Aoki, Keiko Tanabe, Misato Ogino, Sayaka Obayashi, Ken Shirabe","doi":"10.21873/anticanres.17551","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Chemotherapy for breast cancer, particularly with anthracyclines and trastuzumab, is known to induce cardiotoxicity. Pegfilgrastim, a granulocyte colony-stimulating factor analog used to prevent chemotherapy-induced neutropenia, has shown potential myocardial protective effects. This study investigated pegfilgrastim's effect on preoperative chemotherapy-induced cardiotoxicity.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed 110 patients who underwent preoperative chemotherapy from 2010 to 2019 and whose cardiac function was evaluated before and after chemotherapy. All patients received either Adriamycin or Fluorouracil, Epirubicin, and Cyclophosphamide as anthracyclines; in HER2-positive breast cancer, taxanes were combined with anti-HER2 therapy. Cardiac function was evaluated by ultrasound before and after chemotherapy.</p><p><strong>Results: </strong>Sixty-one patients treated with pegfilgrastim were compared to 49 non-treated patients. Cardiac function did not change with chemotherapy in the pegfilgrastim group; however, the ejection fraction with chemotherapy in the non-pegfilgrastim group decreased significantly (<i>p</i>=0.027).</p><p><strong>Conclusion: </strong>Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1707-1712"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.\",\"authors\":\"Takaaki Fujii, Yuko Nakazawa, Mayu Aoki, Keiko Tanabe, Misato Ogino, Sayaka Obayashi, Ken Shirabe\",\"doi\":\"10.21873/anticanres.17551\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Chemotherapy for breast cancer, particularly with anthracyclines and trastuzumab, is known to induce cardiotoxicity. Pegfilgrastim, a granulocyte colony-stimulating factor analog used to prevent chemotherapy-induced neutropenia, has shown potential myocardial protective effects. This study investigated pegfilgrastim's effect on preoperative chemotherapy-induced cardiotoxicity.</p><p><strong>Patients and methods: </strong>We retrospectively reviewed 110 patients who underwent preoperative chemotherapy from 2010 to 2019 and whose cardiac function was evaluated before and after chemotherapy. All patients received either Adriamycin or Fluorouracil, Epirubicin, and Cyclophosphamide as anthracyclines; in HER2-positive breast cancer, taxanes were combined with anti-HER2 therapy. Cardiac function was evaluated by ultrasound before and after chemotherapy.</p><p><strong>Results: </strong>Sixty-one patients treated with pegfilgrastim were compared to 49 non-treated patients. Cardiac function did not change with chemotherapy in the pegfilgrastim group; however, the ejection fraction with chemotherapy in the non-pegfilgrastim group decreased significantly (<i>p</i>=0.027).</p><p><strong>Conclusion: </strong>Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 4\",\"pages\":\"1707-1712\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17551\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17551","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.
Background/aim: Chemotherapy for breast cancer, particularly with anthracyclines and trastuzumab, is known to induce cardiotoxicity. Pegfilgrastim, a granulocyte colony-stimulating factor analog used to prevent chemotherapy-induced neutropenia, has shown potential myocardial protective effects. This study investigated pegfilgrastim's effect on preoperative chemotherapy-induced cardiotoxicity.
Patients and methods: We retrospectively reviewed 110 patients who underwent preoperative chemotherapy from 2010 to 2019 and whose cardiac function was evaluated before and after chemotherapy. All patients received either Adriamycin or Fluorouracil, Epirubicin, and Cyclophosphamide as anthracyclines; in HER2-positive breast cancer, taxanes were combined with anti-HER2 therapy. Cardiac function was evaluated by ultrasound before and after chemotherapy.
Results: Sixty-one patients treated with pegfilgrastim were compared to 49 non-treated patients. Cardiac function did not change with chemotherapy in the pegfilgrastim group; however, the ejection fraction with chemotherapy in the non-pegfilgrastim group decreased significantly (p=0.027).
Conclusion: Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
